Use of Racemic Mixtures of Valnoctamide for Treating Bipolar Disease

Bialer Meir, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research


The technology applies the use of racemic valnoctamide (VCD) for the treatment of bipolar disorder, including the manic phase, for young women of childbearing age.

Valproic acid (VPA) is one of the major antiepileptic drugs used today, having a wide use in both generalized and partial epilepsies.  However due to its teratogenicity, its use in young women is limited.

 Valnoctamide (VCD), an amide analogue of VPA, having anti-convulsant activity was found to be distinctly less teratogenic than VPA. As such, it was found to be distinctly less teratogenic than Valproic acid (VPA) thus enabling its use for treating bipolar disorder for young women.

A bipolar disorder is a form of a depressive disease that characteristically involves cycles of depression and elation or mania. The disorder is often a chronic recurring condition deteriorating one’s quality of life.

Patent Status

Granted US 8,399,708; Israel 188104

Contact for more information:

Shoshana Keynan
VP, Head of Business Development, Healthcare
Contact ME: